Article Information
- Received March 2, 2012
- Accepted April 10, 2012
- Published online June 20, 2012.
Article Versions
- Earlier version (April 10, 2012 - 10:57).
- You are viewing the most recent version of this article.
Author Information
- Hong Su,
- David W. Boulton,
- Anthony Barros Jr.,
- Lifei Wang,
- Kai Cao,
- Samuel J. Bonacorsi Jr.,
- Ramaswamy A. Iyer,
- W. Griffith Humphreys and
- Lisa J. Christopher
- Departments of Pharmaceutical Candidate Optimization (H.S., A.B., L.W., R.A.I., W.G.H., L.J.C.), Discovery Medicine and Clinical Pharmacology (D.W.B.), and Radiochemistry (K.C., S.J.B.), Bristol-Myers Squibb Research, Princeton, New Jersey
- Address correspondence to:
Dr. Lisa J. Christopher, Department of Biotransformation Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research, P.O. Box 4000 Mail Stop F13-01, Princeton, NJ 08543. E-mail: lisa.christopher{at}bms.com
Parts of this work were previously presented as follows: Christopher LJ, Su H, Barros A Jr, Wang L, Cao K, Bonacorsi S Jr, Iyer RA, and Humphreys WG (2009) Identification of the enzymes involved in the oxidative metabolism of saxagliptin and kinetics of formation of its major hydroxylated metabolite; Abstract 289. 16th North American Regional International Society for the Study of Xenobiotics Meeting; 2009 Oct 18–22; Baltimore, MD. International Society for the Study of Xenobiotics, Washington, DC; Su H, Christopher LJ, Iyer RA, Cao K, Bonacorsi S Jr, and Humphreys W (2011) In vivo disposition and pharmacokinetics and in vitro inhibition and induction profiles of [14C]saxagliptin, a potent inhibitor of dipeptidyl peptidase 4, in human. Abstract P236. 17th North American Regional International Society for the Study of Xenobiotics Meeting; 2011 Oct 16–20; Atlanta, GA; International Society for the Study of Xenobiotics, Washington, DC.
